🎯 Fluoroscopy-Guided Epidural Steroid Injection Simulator

Lumbar Radiculopathy — Selecting Patients for Epidural Steroid Injection

Fluoroscopy-guided epidural steroid injection (ESI) is the most frequently performed interventional pain procedure in the United States, targeting inflamed nerve roots compressed by disc herniation, spinal stenosis, or foraminal narrowing. Appropriate patient selection — anchored to concordant imaging, exam findings, and a defined trial of conservative therapy — is the single largest determinant of a successful outcome, per NASS and ASIPP (American Society of Interventional Pain Physicians) appropriate-use guidance.

• >2.4 M: Annual U.S. ESI volume (Medicare fee-for-service claims/yr)
• ≥6 wks: Conservative trial before ESI (NASS guideline threshold)
• required: MRI–symptom concordance (level matches dermatome)
• ~60%: Disc herniation as cause (of lumbar radiculopathy referrals)

Pathophysiology of radicular pain

Radicular pain arises from mechanical compression AND chemical irritation of a nerve root:

• Mechanical component: herniated nucleus pulposus, hypertrophied facet/ligamentum flavum, or foraminal stenosis compresses the dorsal root ganglion or nerve root, producing ectopic discharge and mechanosensitivity • Chemical/inflammatory component: nucleus pulposus material is intrinsically inflammatory — phospholipase A2, tumor necrosis factor-alpha (TNF-α), interleukin-6, and nitric oxide leak from a ruptured annulus and sensitize the nerve root even without gross compression • This dual mechanism explains why small disc herniations can cause severe pain (chemical radiculitis) and why corticosteroids — potent inhibitors of phospholipase A2 and cytokine cascades — have a rational mechanism of benefit independent of any mechanical decompression

Classic presentation: unilateral leg pain radiating below the knee in a dermatomal distribution, often exceeding back pain in intensity ("leg pain > back pain" is a favorable predictor of ESI response), accompanied by a positive straight-leg raise test and a matching neurologic deficit (L5: diminished great-toe extension; S1: diminished ankle reflex and plantarflexion).

Diagnostic work-up and imaging correlation

A structured work-up precedes any injection:

• History: dermatomal leg pain pattern, duration, aggravating/relieving positions (worse sitting/flexion suggests discogenic; worse standing/extension suggests stenosis) • Physical exam: straight-leg raise (sensitivity ~91% for L5-S1 herniation, low specificity), crossed straight-leg raise (high specificity, low sensitivity), myotomal strength testing, reflexes, dermatomal sensory testing • MRI without contrast: gold standard; must show a lesion concordant with the clinical dermatome — an L5-S1 paracentral disc protrusion in a patient with S1 symptoms, not an incidental L3-4 bulge • Electrodiagnostic studies (EMG/NCS): reserved for equivocal cases or to differentiate radiculopathy from peripheral neuropathy/plexopathy when imaging is ambiguous • Selective nerve root block: itself diagnostic when the anatomic level is uncertain (e.g., transitional anatomy, multilevel disease)

Red flags mandating urgent surgical referral rather than injection: progressive motor deficit, cauda equina syndrome (saddle anesthesia, bowel/bladder dysfunction), or suspected infection/malignancy.

Appropriate-use criteria and guideline framework

Multiple societies converge on a similar algorithm before proceeding to fluoroscopically guided ESI:

• NASS (North American Spine Society): ESI is an option for subacute/chronic radicular pain after failure of ≥6 weeks of conservative therapy (activity modification, NSAIDs, physical therapy), with imaging-confirmed concordant pathology • ASIPP (American Society of Interventional Pain Physicians): recommends fluoroscopic (not blind/landmark) guidance as standard of care, citing needle misplacement rates up to 30–40% with blind interlaminar technique • ASRA Pain Medicine (American Society of Regional Anesthesia and Pain Medicine): publishes anticoagulation-management guidelines for neuraxial procedures — ESI is classified as a low-to-intermediate bleeding-risk procedure; antiplatelet/anticoagulant timing must be individualized (e.g., hold warfarin until INR normalizes, hold DOACs 2–3 half-lives) • Spine Intervention Society (SIS, formerly ISIS): publishes the most detailed technical practice guidelines for needle trajectory, contrast confirmation, and complication avoidance referenced throughout this simulation

Realistic expectation-setting is essential: ESI is a palliative, not curative, intervention — it is intended to reduce inflammation enough to permit progression through an active physical therapy program, not to reverse the structural lesion.

A landmark predictor of ESI response is symptom chronicity: patients treated within 3 months of radicular symptom onset have substantially higher response rates than those with symptoms present for over a year, reinforcing early referral rather than prolonged trials of oral therapy alone.

C-Arm Positioning — AP, Lateral, and Oblique Views for Safe Needle Trajectory Planning

Correct fluoroscopic setup is the technical foundation of a safe epidural injection. Before any needle is introduced, the C-arm must produce a true AP view (squared endplates, spinous process centered between pedicles) to avoid an oblique trajectory that misjudges depth, and — for the transforaminal approach — an ipsilateral oblique view producing the classic "Scotty dog" silhouette that exposes the safe entry corridor beneath the pedicle.

• 15–20°: Typical oblique rotation (TFESI) (ipsilateral, for Scotty dog view)
• <5°: Endplate squaring tolerance (cephalad/caudad tilt for true AP)
• 1–2 mL: Skin entry local anesthetic (1% lidocaine, 25–27G wheal)
• 1.5–4 mGy: Fluoro dose per case (typical) (air kerma, pulsed low-dose mode)

The "Scotty dog" and safe-triangle anatomy for transforaminal approach

On a 15–20° ipsilateral oblique lumbar view, the posterior bony elements form the classic "Scotty dog" silhouette used to orient transforaminal needle placement:

• The pedicle forms the "eye" of the dog • The transverse process forms the "nose" • The superior articular process forms the "ear" • The pars interarticularis forms the "neck" (the site of spondylolysis fractures) • The inferior articular process and lamina form the front and rear "legs"

Kambin's safe triangle is the working corridor for transforaminal needle placement, bounded by: • Superiorly: the exiting nerve root and inferior border of the pedicle above • Medially: the traversing nerve root and lateral border of the dural sac • Inferiorly (hypotenuse): the superior endplate of the vertebra below

The target point is the 6 o'clock position of the pedicle on AP view ("subpedicular" approach) — just below and lateral to the pedicle shadow, keeping the needle lateral enough to avoid the traversing root medially and low enough to avoid the exiting root superiorly.

Interlaminar view and midline needle planning

For the interlaminar approach, the target window is the interlaminar space — the gap between adjacent laminae bridged by the ligamentum flavum, most commonly accessed at L4-5 or L5-S1 given their relatively wide interlaminar spaces:

• A true AP view centers the spinous processes symmetrically between the pedicles at the target level, with endplates squared (no double-line/step-off) to confirm no cephalad-caudad tilt • A lateral view is used intermittently during needle advancement to judge depth relative to the spinolaminar line, which approximates the posterior margin of the epidural space • A paramedian trajectory (needle entry 1–2 cm off midline, angled ~15–20° toward midline) is often preferred over strict midline entry because it avoids traversing the interspinous ligament, which has an inconsistent "give" that makes loss-of-resistance less reliable, and reduces the chance of an inadvertent midline dural puncture in patients with prior laminectomy

Unlike the transforaminal approach, interlaminar ESI delivers medication into the posterior epidural space and relies on cephalad/circumferential spread to reach the ventral epidural space and the site of pathology — spread that contrast confirmation in Stage 4 must verify.

Patient positioning, sterile technique, and radiation safety

Standard setup sequence:

1. Prone positioning on a radiolucent fluoroscopy table with a pillow under the abdomen to reduce lumbar lordosis and open the interlaminar spaces 2. Time-out / procedural pause confirming patient identity, laterality, and target level against the imaging and consent 3. Sterile skin prep (chlorhexidine-alcohol) and fenestrated drape; sterile gloves and, per many practice guidelines, a surgical mask for the proceduralist 4. C-arm draped sterilely if positioned within the sterile field; radiation shielding (lead apron, thyroid shield, and where available a lead-glass barrier or mobile shield) for staff 5. Local anesthetic skin wheal (1% lidocaine) at the planned entry point, followed by deeper infiltration along the anticipated needle path 6. ALARA principle (As Low As Reasonably Achievable): pulsed fluoroscopy at the lowest frame rate/dose that maintains adequate image quality, last-image-hold to minimize continuous beam-on time, and collimation to the region of interest reduce both patient and operator dose substantially compared with continuous high-dose fluoroscopy

Landmark-guided ("blind") interlaminar ESI without fluoroscopy has documented needle-tip misplacement (extra-epidural injection) rates as high as 30–40% even in experienced hands, which is why fluoroscopic or CT guidance is now considered standard of care by ASIPP, SIS, and most payer policies.

Needle Trajectory — Kambin's Safe Triangle and the Interlaminar Loss-of-Resistance Technique

Advancing the spinal needle is a stepwise, image-checked process rather than a single continuous thrust: the needle is walked in small increments under intermittent fluoroscopic confirmation, with the operator alternating between AP and lateral (or oblique) views to triangulate the tip position in three dimensions before any injectate is delivered.

• 22–25G: Needle gauge (typical) (Quincke tip, 3.5–5 inch)
• posterior 1/3: TFESI target depth (lateral) (of neural foramen)
• saline or air: Interlaminar LOR medium (loss-of-resistance syringe)
• ~15–30%: Contact-with-nerve response (transient paresthesia reported)

Transforaminal technique — subpedicular walk-off

Step-by-step transforaminal needle advancement:

1. Skin entry is planned 6–10 cm lateral to midline (varies with body habitus) so the needle trajectory, viewed "down the barrel" on the oblique view, appears as a single dot — confirming a true tunnel-vision alignment with the target 2. The needle is advanced under intermittent oblique fluoroscopy toward the 6 o'clock subpedicular position, frequently contacting the inferior articular process or transverse process first as an intentional "bony wall" that is then walked off medially and inferiorly into the foramen 3. Depth is cross-checked on a true lateral view: the tip should rest in the posterior (dorsal) third of the neural foramen, avoiding the anterior two-thirds where the segmental artery of Adamkiewicz-type radiculomedullary vessels may course 4. On AP view, the final tip position sits just below and slightly lateral to the pedicle shadow — medial to this risks needling the traversing nerve root or thecal sac; too far lateral misses the epidural target entirely 5. If the patient reports a paresthesia concordant with their usual radicular pain, the needle is withdrawn 1–2 mm before injection — this indicates the needle tip is touching or very near the nerve, and injecting on top of a paresthesia risks intraneural injection

Because the artery of Adamkiewicz (the dominant anterior spinal artery feeder, most commonly arising T9–L2 but variable) and other radiculomedullary arteries can travel with the exiting nerve root through the foramen, keeping the needle tip in the dorsal/superior "safe" quadrant of the foramen and confirming no vascular uptake before injection are critical steps to prevent the rare but catastrophic complication of spinal cord infarction.

Interlaminar technique — loss of resistance to the epidural space

Step-by-step interlaminar needle advancement:

1. An 18–20G Tuohy or 22–25G Quincke needle is advanced through the skin wheal in a paramedian trajectory toward the interlaminar space, using intermittent AP/lateral fluoroscopy for coarse guidance 2. Once the needle engages the ligamentum flavum (recognized by increased tissue resistance and, often, a subtle "give" as the tip nears the flavum-epidural junction), fluoroscopy is paused and a loss-of-resistance (LOR) syringe filled with saline or air is attached 3. Constant or intermittent gentle pressure is applied to the LOR syringe plunger while the needle is advanced in 1–2 mm increments; a sudden loss of resistance signals passage through the ligamentum flavum into the epidural space 4. Lateral fluoroscopy at this point should show the needle tip at or just anterior to the spinolaminar line, confirming the LOR was not a false-positive from a tissue plane or interspinous gap 5. A gentle aspiration test checks for cerebrospinal fluid (dural puncture) or blood (vascular placement) before contrast is injected

Compared with the transforaminal route, the interlaminar approach places the needle tip in the posterior epidural space rather than directly at the ventral/foraminal site of pathology, trading a small amount of anatomic precision for a lower theoretical vascular-injury profile — the rationale behind many practices defaulting to interlaminar technique for bilateral or multilevel central stenosis presentations.

The Epidurogram — Confirming Needle-Tip Position and Excluding Vascular Uptake

No epidural steroid should be injected until contrast confirms three things: the needle tip is truly epidural (not subdural, intrathecal, or soft-tissue), the contrast spreads to cover the target nerve root or level, and there is no vascular uptake. Digital subtraction fluoroscopy — which electronically removes the static bony background — dramatically increases the sensitivity for detecting the thin, fast-flowing streak of an intravascular injection that can be invisible on standard live fluoroscopy.

• Iohexol: Contrast agent (nonionic, Omnipaque 240/300)
• 0.5–2 mL: Typical volume used (per level, injected slowly)
• 8.9–21.3%: Reported vascular uptake rate (transforaminal lumbar (literature range))
• ~3–4×: Digital subtraction benefit (higher detection vs. live fluoro alone)

Reading the epidural contrast pattern

A correctly placed transforaminal injection produces a recognizable sequence of contrast appearances:

• Initial neurogram: contrast first outlines the exiting nerve root as a thin tubular filling defect coursing along the foramen — direct visual confirmation the needle tip is peri-neural/epidural, not intraneural (an intraneural injection instead produces a dense, sausage-shaped, non-flowing collection that should prompt immediate needle repositioning) • Epidural spread: contrast then tracks medially into the epidural space, often producing the classic "Christmas tree" pattern as it outlines the traversing nerve root sleeves and epidural fat planes bilaterally and cephalad/caudad from the injection level • A well-placed interlaminar injection shows a similar epidural spread pattern but originating from the posterior epidural space, tracking ventrally and to the sides, ideally reaching 1–2 levels above and below the target

Unwanted patterns that mandate needle repositioning: • Intrathecal (myelographic) spread: contrast outlines individual nerve roots within a well-defined thecal sac contour with a sharp, undulating "flame" pattern — indicates dural puncture • Subdural spread: contrast forms an irregular, "railroad track" or feathery pattern that spreads slowly and disproportionately for the injected volume • Vascular uptake: contrast disappears rapidly along a linear or serpiginous vascular course, often visible only for one or two fluoroscopy frames — this is the specific finding digital subtraction is designed to catch

Why vascular uptake matters — the case for non-particulate steroid

Reported rates of inadvertent intravascular needle placement during transforaminal ESI, detected by contrast injection under real-time or digital subtraction fluoroscopy, range from roughly 8.9% to over 20% depending on spinal level and technique (higher at L5-S1 and in cervical injections). Importantly, aspiration through the needle before injecting is unreliable — it fails to detect a substantial fraction of cases that contrast injection reveals, because small-gauge needles can be intravascular yet still yield a negative aspirate.

The clinical significance is greatest when the injectate is a particulate corticosteroid (methylprednisolone, triamcinolone): particulate steroid crystals injected into a radicular artery can embolize and occlude the vessel, and if that vessel is a critical feeder to the anterior spinal artery (e.g., in the region of the artery of Adamkiewicz), the result can be spinal cord infarction and permanent paraplegia — a rare but catastrophic and irreversible complication that has been reported predominantly with cervical and, less commonly, lumbar transforaminal injections.

This risk is the direct rationale behind current practice recommendations (Spine Intervention Society, ASRA, and multi-society consensus statements) to use non-particulate corticosteroids (dexamethasone) for all transforaminal injections, reserving particulate steroids for interlaminar or caudal approaches where the needle tip is farther from a radicular artery.

Multi-society guidelines (including FDA safety communications following a 2014 review) now recommend non-particulate dexamethasone as the first-line agent for cervical and lumbar transforaminal epidural injections specifically because of the vascular embolization risk demonstrated by contrast studies — a direct example of imaging findings changing pharmacologic practice.

Delivering the Injectate and Interpreting the Evidence Base for Epidural Steroid Injection

Once contrast confirms an accurate, non-vascular, non-intrathecal needle position, the therapeutic injectate — a corticosteroid combined with a small volume of local anesthetic or saline — is delivered slowly with intermittent aspiration. The clinical literature supports meaningful short-term relief for well-selected patients, though effect sizes are modest and diminish over time, framing ESI as a bridge to rehabilitation rather than a definitive cure.

• 50–70%: ≥50% pain relief at 2–6 wks (well-selected radicular pain cohorts)
• often <3 mo: Relief durability (benefit wanes by 3-month mark)
• ~3–7: Number needed to treat (for meaningful short-term relief)
• <1%: Serious complication rate (infection, dural puncture, hematoma)

Injectate composition and delivery technique

Typical injectate formulations:

• Transforaminal lumbar ESI: dexamethasone 4–10 mg (non-particulate) mixed with preservative-free normal saline or 0.25% bupivacaine, total volume 1.5–3 mL per level • Interlaminar lumbar ESI: triamcinolone 40–80 mg or methylprednisolone 40–80 mg (particulate agents acceptable given the posterior epidural target, farther from radicular arteries) combined with preservative-free saline or dilute local anesthetic, total volume 4–6 mL • Caudal ESI (an alternative low-risk route through the sacral hiatus): larger volumes (8–10 mL) of dilute steroid/local anesthetic/saline mixture, used when a large-volume "neuroplasty-like" spread is desired or when anatomy precludes lumbar approaches (e.g., prior fusion hardware)

Injection is performed slowly (over 30–60 seconds) with repeat gentle aspiration every 0.5–1 mL to re-check for delayed flash of blood or CSF, since needle-tip position can shift subtly during injection due to tissue plane changes or patient movement.

Evidence base — effectiveness and comparative studies

The clinical trial literature on ESI is large but heterogeneous, with the following broad conclusions supported by systematic reviews (including Cochrane reviews and specialty-society technology assessments):

• For acute/subacute lumbar radicular pain due to disc herniation, transforaminal and interlaminar ESI both provide short-term (2–6 week) pain relief superior to placebo/saline injection in most randomized trials, with effect sizes generally described as small-to-moderate • Comparative trials (e.g., Kennedy et al. and related transforaminal-vs-interlaminar comparisons) suggest transforaminal injection may achieve a modestly higher short-term response rate for unilateral radicular pain concordant with a single nerve root, consistent with its more targeted delivery to the ventral epidural space and foramen • Benefit is substantially less consistent for axial (non-radicular) low back pain or for degenerative changes without a clear compressive/inflammatory nerve root lesion — ESI is not indicated as first-line therapy for mechanical low back pain • Repeat injections beyond a defined series (commonly limited to 3–4 per year at a given level in many payer and society guidelines) show diminishing incremental benefit and are discouraged as a substitute for definitive diagnosis or surgical evaluation when symptoms persist

ESI functions best as an adjunct that reduces pain enough to allow effective participation in physical therapy and functional restoration, rather than as a stand-alone cure — a distinction emphasized in NASS and ASIPP outcome-reporting recommendations.

Complications and safety profile

Fluoroscopically guided ESI has a favorable overall safety profile, though a spectrum of complications is recognized:

• Minor/self-limited: post-procedure soreness at the injection site, transient increase in pain ("steroid flare," typically 24–48 hours), vasovagal response, transient facial flushing (more common with dexamethasone), and transient hyperglycemia in diabetic patients (steroid effect lasting days) • Dural puncture / post-dural-puncture headache: more common with interlaminar approach and larger-gauge needles; managed conservatively (hydration, caffeine, rest) or with an epidural blood patch if severe/persistent • Infection: epidural abscess or discitis is rare (<0.1–0.01%) but represents a serious complication requiring strict sterile technique and vigilance for delayed presentation of fever, worsening pain, or new neurologic deficit • Epidural hematoma: rare, higher risk in anticoagulated patients — underscores the importance of following ASRA Pain Medicine interventional-procedure anticoagulation guidelines before proceeding • Vascular injury / spinal cord infarction: the rare but most feared complication of transforaminal injection, discussed in Stage 4, mitigated by digital subtraction contrast confirmation and preferential use of non-particulate steroid • Systemic corticosteroid effects: HPA-axis suppression, transient reduction in bone mineral density with frequent repeated dosing, and — over multiple courses per year — theoretical contribution to accelerated disc/vertebral changes, motivating dose and frequency limits in most society guidelines

Overall serious complication rates for fluoroscopically guided lumbar ESI performed by trained proceduralists are well under 1%, but the rare vascular and infectious complications are largely preventable through meticulous technique: contrast confirmation with digital subtraction, non-particulate steroid for transforaminal injections, sterile technique, and adherence to ASRA anticoagulation guidance.